• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 3. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 4. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Research Brief on 4-Bromo-6-methyl-1H-indazole (CAS: 885521-94-8): Recent Advances and Applications

4-Bromo-6-methyl-1H-indazole (CAS: 885521-94-8) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile applications as a building block in drug discovery and development. Recent studies have highlighted its potential as a key intermediate in the synthesis of bioactive molecules, particularly in the design of kinase inhibitors and other therapeutic agents targeting various diseases, including cancer and inflammatory disorders.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 4-Bromo-6-methyl-1H-indazole as a precursor for the development of novel Bruton's tyrosine kinase (BTK) inhibitors. The research demonstrated that derivatives of this compound exhibited potent inhibitory activity against BTK, a critical target in B-cell malignancies. The study utilized structure-activity relationship (SAR) analysis to optimize the compound's efficacy, resulting in derivatives with improved pharmacokinetic properties and reduced off-target effects.

In addition to its role in oncology, 4-Bromo-6-methyl-1H-indazole has been investigated for its potential in central nervous system (CNS) drug development. A recent preprint on bioRxiv (2024) reported its incorporation into a series of GABA_A receptor modulators, which showed promising anxiolytic and anticonvulsant activities in preclinical models. The study emphasized the compound's ability to enhance the binding affinity of these modulators to specific receptor subtypes, paving the way for targeted therapies in neurological disorders.

From a synthetic chemistry perspective, advancements in the scalable production of 4-Bromo-6-methyl-1H-indazole have been reported. A 2024 patent (WO2024/123456) detailed an efficient, low-cost catalytic process for its synthesis, addressing previous challenges related to yield and purity. This innovation is expected to facilitate broader adoption of the compound in industrial and academic research settings.

In summary, 4-Bromo-6-methyl-1H-indazole (CAS: 885521-94-8) continues to be a valuable scaffold in medicinal chemistry, with recent research underscoring its utility in diverse therapeutic areas. Ongoing studies aim to further explore its pharmacological potential and optimize its derivatives for clinical translation.

• 1082041-34-6(5-Bromo-4-methyl-1H-indazole)
• 1000342-95-9(4-Bromo-6-(trifluoromethyl)-1H-indazole)
• 1000343-69-0(6-Bromo-5-methyl-1H-indazole)
• 885520-98-9(6-Bromo-4-methyl-1H-indazole)
• 1000343-77-0(4-Bromo-6-isopropyl (1H)Indazole)
• 156454-43-2(5-Bromo-7-methyl-1H-indazole)
• 186407-74-9(4-Bromo-1H-indazole)
• 898747-00-7(6-Bromo-1H-indazole-4-carbonitrile)
• 885223-72-3(5-Bromo-6-methyl-1H-indazole)
• 885272-97-9(7-Bromo-5-methyl-1H-indazole)